MK‑2866 (Ostarine, Enobosarm)
Experimental SARM, the most studied of its kind; not approved as a medicine, and it can cause liver damage and suppress the body's own hormones.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
Ostarine vs RAD-140DETAILED OVERVIEW
What is MK-2866 (Ostarine, Enobosarm)?
Ostarine (MK-2866, enobosarm) is an experimental compound, a selective androgen receptor modulator (SARM), meaning a non-steroid substance that acts on the receptor for male hormones. It has never been approved as a medicine, but of all SARMs it has been studied the most in people. In one study in cancer patients, fat-free body mass rose by about 1.3 kg compared with placebo. The large late-phase trials in cancer patients, however, did not reach their goal, so the developing company stopped that development.
It lowers the body's own testosterone production (by about 23% in the trial), worsens cholesterol values, and can cause hair loss and acne; cases of drug-induced liver damage have also been documented. In women it can cause masculinization, and the deepening of the voice is permanent. It must not be used in pregnancy, because it can cause masculinization of the fetus. It leaves the body slowly, so even if a side effect appears, its effect cannot be stopped quickly. It is widespread among bodybuilders, but it is banned in competitive sport all year round.
Mechanism
Non-steroidal selective AR modulator (aryl-propionamide). Strong AR agonist in muscle, moderate prostate.
Anabolic activity (Dalton 2011)
About 1.3 kg gain in lean body mass in cancer-related wasting
Half-life
~24 h (oral)
Onset
2-4 weeks
Legal status
Not approved; large trial failed in 2016; banned by WADA
Ostarine (MK-2866) is generally considered a 'beginner SARM' with a milder profile. It is still effective – especially for preserving muscle in a caloric deficit – but compared to real AAS, it is clearly weaker. Users typically report better recovery, slight strength increases, and a fuller look without significant water retention. It is most popular for muscle preservation during cuts, which is the dominant use-case in community accounts. Side effects to note include HPTA suppression, hair loss, and insomnia. It is also less aggressive than RAD-140. Importantly, despite the mild reputation, Ostarine still impacts lipids meaningfully and should not be considered side-effect-free. It is best characterized as a subtle, smaller anabolic compound rather than a dramatic mass-builder. Administered orally, often dosed about 1 hour before training. Lower doses are typical for muscle preservation; higher doses provide more growth but also more side effects.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS . The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.. J Cachexia Sarcopenia Muscle.
Crawford J, Prado CM, Johnston MA, Zimmers TA, Penna F . Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).. Curr Oncol Rep.
Leciejewska N, Jędrejko K, Gómez-Renaud VM, Manríquez-Núñez J, Muszyńska B, Pokrywka A . Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.. Eur J Clin Pharmacol.
Labban H, Kwait B, Paracha A, Khan A, Singh M, Lopez R . LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.. Cureus.
Vasilev V, Georgieva K, Kraeva M . Selective Androgen Receptor Modulators in Women: What Do We Know, and What Is Still Missing.. Life (Basel).
Safety
Side effects, stop signs, contraindications
Side effects · 7
- HPTA suppression: lowered testosterone, LH and FSH. At the clinical 3 mg/day dose Total T fell ~23% (Dalton 2011); at UGL doses (20-30 mg/day) suppression can be complete, with reduced libido and lethargy.
- Adverse lipid profile: HDL ("good" cholesterol) drops ~20-30%, a class effect of SARMs. Longer or high-dose use shifts the cardiovascular risk profile unfavourably.
- Hepatotoxicity (drug-induced liver injury, DILI): at least 4+ documented hepatocellular injury case reports (Vilaca 2018). In trials ALT/AST rose moderately (~1.5-2x); worse at UGL doses. Mechanism: a CYP3A4-mediated reactive metabolite (Solomon 2019).
- Androgenic effects: hair loss (androgenic alopecia) in genetically predisposed users, plus acne. Milder than with more androgenic SARMs (e.g. RAD-140), but present.
- Virilisation in women: at higher doses masculinisation (voice deepening, increased body hair, clitoral enlargement), which can be partly irreversible. Voice deepening is permanent.
- Insomnia and lethargy: sleep disturbance and fatigue are commonly reported, partly secondary to HPTA suppression.
- Slow clearance due to the long half-life (~24 h): if a side effect appears, the compound cannot be stopped quickly and effects persist for days.
Contraindications · 7
- Pregnancy and breastfeeding: absolutely contraindicated due to the risk of fetal androgenisation and virilisation of a female fetus.
- Pre-existing liver dysfunction or elevated liver enzymes: avoid given the documented DILI cases.
- Concurrent alcohol use or other hepatotoxic agents (e.g. other oral SARMs, 17-alpha-alkylated steroids): cumulative liver burden.
- Planned fatherhood / fertility window: due to HPTA suppression and reduced sperm parameters; full recovery takes 2-4 months.
- Competitive athletes: banned by WADA year-round (S1.2 "other anabolic agents"), urine detection window 2-4 weeks. The most frequent cause of doping suspensions in 2015-2020.
- Undiagnosed or androgen-sensitive conditions (e.g. prostate disease, hormone-sensitive tumours): avoid without medical evaluation.
- Pre-existing dyslipidaemia or cardiovascular risk: the HDL drop further worsens the lipid profile.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.
Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J, Prado CM, Johnston MA, Zimmers TA, Penna F
Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.
Leciejewska N, Jędrejko K, Gómez-Renaud VM, Manríquez-Núñez J, Muszyńska B, Pokrywka A
LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.
Labban H, Kwait B, Paracha A, Khan A, Singh M, Lopez R
Selective Androgen Receptor Modulators in Women: What Do We Know, and What Is Still Missing.
Vasilev V, Georgieva K, Kraeva M
Telegram
Have a question about MK‑2866 (Ostarine, Enobosarm)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.

